caprotec bioanalytics GmbH is the CCMS company. Our mission is to generate better, safer products, quicker to market for the pharmaceutical, agrochemical, and biotech industries.
The core of our proprietary Capture Compound Mass Spectrometry (CCMS) technology consists of small, multi-functional molecules called Capture Compounds®, which are made around any small bioactive molecule. They enable the isolation and identification of the specific target proteins of bioactive molecules directly from complex biological samples in solution. CCMS can be used in any species, tissue or preparation, to access proteins in any compartment, from cell surface to nucleus. Most bioactive agents exert their effects by interacting with specific protein sets. CCMS is the leading, most widely applicable, platform for the isolation and analysis of proteins from complex mixtures. CCMS has enormous potential in facilitating the identification, optimization and development to market of bioactive small molecules and the development of protein biomarkers, thus reducing risk and cost for our life science industry partners.
We have a broad patent portfolio. This, together with our know-how gained over years of focus on cutting edge proteomics, and a highly motivated team renders caprotec the partner of choice for even the most difficult of target identifications, or for rescuing stalling projects.
Caprotec was founded in 2007 by serial entrepreneur Prof. Hubert Koester, and is based in Berlin. Its investors comprise a mix of private and institutional. caprotec profits from a young, vibrant and highly qualified community and surroundings in Adlershof Science Park, one of the leading high tech hubs in Europe.